Fig. 2: Antitumor activity for all patients.
From: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
a, Waterfall plot showing the best percentage decrease from baseline in the tumor burden (defined as the sum of the longest diameters of all target lesions) in all 29 patients. b, Swimmer plot showing the time on study treatment, best response, and reason for treatment discontinuation for all 29 patients. c, Spider plot of the percentage changes from baseline in sum of tumor diameters over time in all 29 patients.
